In this issue:
Predictors of sustained response with tofacitinib in UC
Concordance of cross-sectional imaging with endoscopy postoperative CD
Upadacitinib over 30 months for CD
Infection risk with ustekinumab and tofacitinib for IBD
1-year steroid-free deep remission does not prevent CD progression
IBD risk with sweetened beverages and natural juices
Switching from intravenous to SC vedolizumab maintenance in IBD
Efficacy and safety of infliximab retreatment in CD
Hypophosphataemia after ferric derisomaltose or ferric carboxymaltose in IBD with iron deficiency anaemia
Please login below to download this issue (PDF)